Up 14% in a month, is the Resmed share price just getting started?

The sleep apnoea and respiratory company's shares have had a fine start to FY23.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Resmed shares have pushed higher in the new financial year
  • Healthcare has proven to be a defensive sector in these volatile times
  • In the past 12 months, the Resmed share price is down almost 6%

The ResMed Inc (ASX: RMD) share price has been a solid gainer this past month of trade, up almost 14% in that time.

The company's shares have travelled from a low of $27.63 apiece on 25 May to their current price of $32.34 a share.

Meanwhile, healthcare shares are rebounding in June-July, with the S&P/ASX 200 Health Care Index (ASX: XHJ) up 13% in a month as well. The year-to-date performances of both Resmed and the index are charted below:

TradingView Chart

Has the Resmed share price got more?

The broker Morgans is bullish on the Resmed share price and has a price target of $37.95.

In a recent note, the broker said its long-term view on the healthcare player is positive, despite market volatility.

It made note of Resmed's digital platform that addresses kinks along the "healthcare value chain" in its assessment.

Meanwhile, 64% of brokers rate Resmed as a buy right now, according to Refinitiv Eikon data. The remainder say it's a hold, with no sell ratings on the share.

The consensus price target from this list is $33.93, a fraction above its current share price.

Sector-wise, healthcare shares could catch further bids in FY23 if recent trends prevail.

Researchers at Deloitte recently noted a number of catalysts are pushing the "clinical, financial, and operational transformation" of health care – COVID-19 potentially being one of these.

Moreover, the sector is projected to deliver an average earnings per share (EPS) growth of 30% in the second half of CY2022, according to Bloomberg data.

In the past 12 months, the Resmed share price is down 5.7%, falling just over 9% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »